Targeting Dendritic Cells in Allergen Immunotherapy

https://doi.org/10.1016/j.iac.2006.02.010Get rights and content

Section snippets

What do we know about the mode of action of allergen immunotherapy?

In general, therapeutic strategies used for treating allergic diseases can be subdivided into two major forms: (1) short-term therapeutic strategies that treat the acute symptoms of allergic diseases, and (2) long-term therapeutic strategies, such as allergen-specific immunotherapy, that have the goal of efficient long-term down-regulation of the reactivity toward specific allergens.

Allergen-specific immunotherapy has been shown to be efficient, especially for individuals who have allergic

Why are dendritic cells attractive targets for allergen immunotherapy?

DCs are located at the interface of the body and the environment, such as the skin, respiratory tract, and mucosal sites [2]. Therefore, DCs are easily accessible for immunotherapeutic substances applied through subcutaneous injections or administered to mucosal surfaces such as the sublingual or intranasal mucous membranes. Obviously, DCs not only are one of the first cell types to come in contact with naturally occurring allergens in patients who have allergic diseases but also gain early

Which tolerogenic properties of dendritic cells might be relevant in allergen immunotherapy?

Different studies provide evidence that DCs are critically involved in the induction of tolerance against allergens, which is a major mode of action of immunotherapy. However, the detailed mechanisms converting DCs into tolerogenic DCs in immunotherapy are far from being known. Although increasing insights into the biology of DCs show that these cells may have a critical involvement in the mechanism contributing to the therapeutic response to immunotherapy, most hypotheses concerning the role

Is the high-affinity receptor for IgE (FcεRI) on dendritic cells a key structure in allergen immunotherapy?

The detection of FcεRI on antigen-presenting DC has brought new insights into the distribution and function of this immunoglobulin receptor. FcεRI has been shown to be expressed in a trimeric form, consisting of the IgE-binding α-chain and the γ-chain dimer responsible for signal transduction, in antigen-presenting cells such as monocytes, Langerhans cells (LCs), and other DC subtypes [19].

The function of FcεRI on DCs is still not elucidated in detail, but FcεRI on DCs is known to play opposing

How do the different routes of allergen immunotherapy target dendritic cells?

The classical and most established model for immunotherapy is the subcutaneous immunotherapy for insect sting allergy. In addition, subcutaneous immunotherapy has been used for treating several other allergic sensitizations, such as birch pollen or grass pollen allergy in individuals who have single sensitizations but also allergy to house dust mites and other aeroallergens. Although the mechanisms contributing to the shift from a high reactivity toward allergens to a state of unresponsiveness

Are dendritic cells attractive targets for adjuvants of allergen immunotherapy?

Since several studies proved that the therapeutic effect of immunotherapy accompanies a shift of Th2 toward modified Th2 or Th1 responses, immunotherapy strategies have been developed to coadminister adjuvants with a high capacity to trigger Th1 immune responses and transfer the immune response from innate to adaptive immunity. Most of these adjuvants are bacterial products, such as monophosphoryl lipid A (MPL) or synthetic oligonucleotides containing unmethylated CpG dinucleotides [56], [57].

How does anti-IgE treatment target dendritic cells?

An alternative approach to allergen immunotherapy is to reduce the amount of IgE molecules in the sera of the patients, using anti-IgE antibodies to reduce the number of allergen-specific IgE molecules bound to FcεRI on DCs. These strategies have the goal of preventing the earliest steps of allergic reactions by reducing the frequency of IgE–FcεRI receptor interaction. In summary, treatment with anti-IgE antibodies results in a significant reduction of free IgE molecules in the sera of

What are the future perspectives for dendritic cells as targets for antiallergic treatment strategies?

In summary, DCs play a paradigmatic role in our immune system and are therefore attractive targets of allergy immunotherapeutic strategies, which take advantage of the capability of DCs to act as natural silencers of allergic diseases [24], [69], [70]. The outstanding features qualifying DCs as target cells for allergen immunotherapy include their accessibility for immunotherapy preparations because of their localization at the border zones of the immune system, their capability to selectively

First page preview

First page preview
Click to open first page preview

References (76)

  • N. Novak et al.

    Unraveling the mission of FcepsilonRI on antigen-presenting cells

    J Allergy Clin Immunol

    (2003)
  • S. Rutella et al.

    Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications

    Immunol Lett

    (2004)
  • R.M. Steinman

    The control of immunity and tolerance by dendritic cell

    Pathol Biol (Paris)

    (2003)
  • N. Novak et al.

    FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro

    J Allergy Clin Immunol

    (2004)
  • N. Novak et al.

    IgE receptors

    Curr Opin Immunol

    (2001)
  • A. Mellor

    Indoleamine 2,3 dioxygenase and regulation of T cell immunity

    Biochem Biophys Res Commun

    (2005)
  • A. Boasso et al.

    Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

    Blood

    (2005)
  • A. Boasso et al.

    Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

    Blood

    (2005)
  • C.L. Kepley et al.

    Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils

    J Allergy Clin Immunol

    (2000)
  • L.C. Freytag et al.

    Mucosal adjuvants

    Vaccine

    (2005)
  • H. Tighe et al.

    Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

    J Allergy Clin Immunol

    (2000)
  • J.D. Marshall et al.

    Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy

    J Allergy Clin Immunol

    (2001)
  • M.K. Tulic et al.

    Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response

    J Allergy Clin Immunol

    (2004)
  • T. Feuchtinger et al.

    Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season

    J Allergy Clin Immunol

    (2003)
  • D.W. O'Neill et al.

    Manipulating dendritic cell biology for the active immunotherapy of cancer

    Blood

    (2004)
  • C.L. Kepley et al.

    FcepsilonRI-FcgammaRII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells

    Clin Immunol

    (2003)
  • B. Linhart et al.

    A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination

    J Allergy Clin Immunol

    (2005)
  • K. Hufnagl et al.

    Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice

    J Allergy Clin Immunol

    (2005)
  • J. Reisinger et al.

    Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity

    J Allergy Clin Immunol

    (2005)
  • N. Novak et al.

    The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies

    Allergy

    (2004)
  • M. Rossi et al.

    Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity

    J Immunol

    (2005)
  • P.G. Holt et al.

    Sensitization to airborne environmental allergens: unresolved issues

    Nat Immunol

    (2005)
  • A.B. Kay

    Allergy and allergic diseases. First of two parts

    N Engl J Med

    (2001)
  • A.B. Kay

    Allergy and allergic diseases. Second of two parts

    N Engl J Med

    (2001)
  • M.A. Wallet et al.

    Immunoregulation of dendritic cells

    Clin Med Res

    (2005)
  • K. Gehlhar et al.

    Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome

    Clin Exp Allergy

    (1999)
  • M. Jutel et al.

    Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures

    J Immunol

    (1995)
  • M. Jutel et al.

    IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

    Eur J Immunol

    (2003)
  • Cited by (24)

    • Evaluation of size and dose effects of rChe a 3 allergen loaded PLGA nanoparticles on modulation of Th2 immune responses by sublingual immunotherapy in mouse model of rhinitis allergic

      2019, International Journal of Pharmaceutics
      Citation Excerpt :

      The results indicated that protein integrity and ability of the protein to bind to IgG and IgE was not significantly affected during encapsulation process (Sharif and Wheeler, 1995). Different studies demonstrated that DCs are critically involved in the induction of tolerance against allergens, which is a major mode of action of immunotherapy (Novak, 2006). On the other hand, antigen uptake by DCs resulted to Th1 response induction and therefore tolerance (Hamdy et al., 2011; Rebouças et al., 2012).

    • Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors

      2016, European Journal of Medicinal Chemistry
      Citation Excerpt :

      As a heme-containing extrahepatic and intracellular monomeric enzyme, IDO1 is widely expressed in many organs, tissues and cell types [7–10]. Due to its indispensable immunomodulatory roles in pregnancy [11,12], cancer [13], allergy [14] and the proverbial central nervous system disorders Alzheimer’s disease [15], IDO1 has emerged as a significant new therapeutic target. However, in contrast to the thorough studies on IDO1, the physiological and pathological roles of IDO2 have, to a large extent, remained unclear.

    • Atopic donor status does not influence the uptake of the major grass pollen allergen, Phl p 5, by dendritic cells

      2015, Journal of Immunological Methods
      Citation Excerpt :

      Sharquie, I. et al. demonstrated a modest percentage (43%) of FcϵRI expression and high expression of CD23 (91%) on immature MoDCs during in vitro generation from peripheral blood monocytes (Sharquie et al., 2013). The relationship between levels of serum IgE, cell-bound IgE and IgE receptors has been shown in previous studies (Novak, 2006; Lundberg et al., 2008; Dehlink et al., 2010; Sharquie et al., 2013). In our study, we used serum free medium to generate MoDCs and were unable to detect specific IgE in supernatants from immature MoDCs on day 7 (data not shown).

    • Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells

      2015, Biomaterials
      Citation Excerpt :

      This indicates that both size and ligand influence the immunological effector response. Thus, small zwitterion-stabilized particles may be advantageous for immunosuppression therapy [8,16,27]. Cytokine secretion by DCs and PBLs.

    View all citing articles on Scopus

    This work was supported by grants from the Deutsche Forschungsgemeinschaft DFG NO 454/2-3, DFG NO454/1-3 and grants from the University of Bonn, BONFOR. N. Norak is supported by a Heisenberg Fellowship of the DFG.

    View full text